| Literature DB >> 33878916 |
Keitaro Shimozaki1, Yasutaka Sukawa2, Yasunori Sato3, Sara Horie1, Akihiko Chida1, Kai Tsugaru1, Kazuhiro Togasaki1, Kenta Kawasaki1, Kenro Hirata1, Hideyuki Hayashi4, Yasuo Hamamoto1, Takanori Kanai1.
Abstract
The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.Entities:
Keywords: Fine–Gray regression model; PD-1; Type I hypersensitivity reaction; immune checkpoint inhibitors; immune-related adverse events; risk factor
Mesh：
Substances：
Year: 2021 PMID： 33878916 DOI： 10.2217/fon-2020-0861
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404